术前ET与CEF新辅助化疗方案治疗乳腺癌的临床观察  

Clinical evaluation of ET and CEF regimens for neoadjuvant chemotherapy in the treatment of breast cancer

作　　者：王冰涛[1] 马向涛[1] 姚金华[1] 余力伟[1] 

机构地区：[1]北京海淀医院外科,100080

出　　处：《北京医学》2007年第11期658-660,共3页Beijing Medical Journal

摘　　要：目的比较两种不同新辅助化疗方案治疗乳腺癌的疗效及不良反应。方法46例II、III期乳腺癌患者随机分为ET组和CEF组,每组23例,分别用ET、CEF化疗方案治疗,3周为1个周期。所有患者完成3周期新辅助化疗后评价疗效。结果乳腺癌总有效率(OR)ET组为87.0%(20/23),CEF组为61.0%(14/23)。两组之间有显著性差异(P﹤0.05)。主要不良反应恶心、呕吐、厌食、脱发两组相似,ET组骨髓抑制并伴有关节肌肉疼痛及神经毒性。结论两组新辅助化疗方案对乳腺癌的原发肿瘤均有效,不良反应均可耐受。ET组疗效及不良反应均高于CEF组。Objective This study was designed to compare the efficacy and side effects of ET and CEF neoadjurant chemotherapy regimens in the treatment of breast cancer. Methods Forty-six patients with stage Ⅱ and Ⅲ breast cancers were randomly divided into two groups, and received ET or CEF regimen every 3 weeks for 3 cycles. Clinical responses were assessed after 3 cycles of neoadjuvant chemotherapy. Results The overall response rate （OR） was 87.0% （20/23） in ET and 61.0% （14/23） in CEF respectively. There was significant difference between the two groups（P 〈 0.05）. The side effects, including nausea, vomiting, anorexia, alopecia, were similar in the two groups; leucopenia, myalgia and neurotoxicity were more prominent in ET regimen. Conclusions The two different regimens are all effective in the treatment of breast cancer, and is well tolerated. ET regiment is more effective but with more side effects than CEF regimen.

关 键 词：乳腺癌 新辅助化疗 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]